Osterborg 2002.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 349, multiple myeloma, Non‐Hodgkin lymphoma, chronic lymphocytic lymphoma; concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = 150 IU/kg sc TIW hb‐target = 13‐14 g/dL planned ESA duration = 16 weeks
Outcomes	Primary: transfusion free survival; secondary: Hb response, time to response, number of blood transfusions, QoL, safety
Notes	study number = 77914
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	randomization program
Allocation concealment?	Low risk	central randomization